UBE2C inhibition sensitizes breast cancer cells to treatment with radiation and doxorubicin (alkylating agent), as well as to anti-hormonal agents such as tamoxifen (estrogen receptor modulator) and letrozole (nonsteroidal aromatase inhibitor) [60]. This evidence concerns the gene UBE2C and breast carcinoma.